SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MJ who wrote (1175)11/24/1998 7:58:00 AM
From: Tom Genna  Read Replies (2) of 1510
 
Although information I've read has not identified why cells go "rogue" and begin attacking the body, IR501 goes as far as to attack the problem at the "rogue cell" level by causing the body to eliminate them. We do not know from the published trial results if this stimulus will last if administration of the drug stops. However, if the drug does work as described so far then the drug will/may prevent the progression of the disease and the attendant physical destruction.

I might add that although the results that have been published to date may ultimately be significant enough for approval I really hope that phase IIb and III results are able to approach the level of success of Enbrel whose users boast an 80+% ACR20 score. Look at IMNX stock and see the value of that kind of relief for it's users. There lies the current "Holy Grail."

good luck.........tomster
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News